Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
1. Modeyso is the first treatment option for H3 K27M-mutant glioma. 2. NCCN Guidelines recommend Modeyso as a category 2A single-agent treatment. 3. FDA approved Modeyso based on efficacy from 50 patients in clinical studies. 4. 33% of patients experienced serious adverse reactions during trials. 5. Modeyso's market introduction may shift treatment landscape for glioma patients.